Navigation Links
ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Date:12/5/2007

her information, visit http://www.ariusmabs.com.

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ... stem cell biotechnologies. Currently the company holds seven ... patent applications currently under examination by the U.S. Patent ... of the most vexing problems in adult stem cell ... are difficult to identify; and they have been difficult ...
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 0 clinical testing has been gaining acceptance and ... development process in the years to come. The ... and technology dependence is also expected to result ... in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There is every ...
... Health Care Business Conference, an MBA-student organized event, will be held ... distinguished speakers and panelists from Healthcare Services, Investment, Pharma, Biotech, and ... ... 10, 2009 -- The 2009 Wharton Health Care Business Conference ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:7/31/2014)... LA Dr. Oren Tessler, Assistant Professor of Clinical ... of Medicine, is part of a team of plastic ... using a method to screen and select patients for ... of the patients who underwent this surgery to decompress ... got a bonus cosmetic eyelid surgery. The study, which ...
(Date:7/31/2014)... NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... and consumers wanting to learn more about its  ... on-air today, July 31 st . ... featured in a segment of NewsWatch, a weekly ... the History Channel, FYI Network today. ...
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... choices for our nation,s schoolchildren is a hot-button issue ... team of researchers from Cornell University have recently identified ... vegetables and salad items. Laura Smith, a researcher ... findings of the study "Convenience Drives Choice in School ...
... Inc. (Nasdaq: OKSB ), ("Southwest"), today announced that it has priced its ... the public of $12.50 per share for net proceeds of approximately ... size of approximately $40 million .  The offering is expected to close ... , , ...
... PHILADELPHIA , April 27 Mondre Energy, Inc. (MEI), a ... Exeter Associates to address a wide range of energy issues on behalf ... Power Plant Research Program works to ensure that Maryland meets ... , , ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: